Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Jan 11, 2023 9:40am
229 Views
Post# 35215473

RE:RE:RE:RE:RE:RE:What a scrap.

RE:RE:RE:RE:RE:RE:What a scrap.C'mon bball, on Sept 20th you said you own more than half of 1% of this company. Nov 19, you said you were invitied to a presentation with JMP Securities participating were Gail, Neil Cashman, Joanne Kaplan, Larry Altsteil, Eugene Williams. Sounds like some inside information not privy to other shareholders. Positng about investor relations and so on.... really surprized that you were able to sway fan support like RC and Goldtech after all the misses. 

Promis "In April 2022, we submitted a type B Pre-IND meeting package. FDA's written feedback on the proposed preclinical and clinical strategy to support submission of the IND was recieved in May 2022, and the IND is in preparation."

Earlier Promis said they would be filing the IND in the second half of 2022, then the fourth quarter, then by the end of the year. I don't believe they have filed. 
<< Previous
Bullboard Posts
Next >>